Operations begin at new Genezen lentiviral and retroviral vector lab in Indianapolis

By Jane Byrne contact

- Last updated on GMT

Ribbon cutting ceremony for new lab © Genezen
Ribbon cutting ceremony for new lab © Genezen

Related tags: lentiviral vector, retroviral, Cell lines, upstream, cell and gene therapy

Genezen, a cell and gene therapy focused CDMO, has just opened a new process development and analytical lab, a build that represents the first phase of a 75,000+ square foot cGMP-compliant lentiviral and retroviral vector production facility in Indianapolis.

The next phase, with cGMP production suites, is currently underway and due to complete in early 2022.

The lab, said the CDMO, will deliver a full suite of process development capabilities to support cGMP and commercial readiness, upstream and downstream process improvements, research grade and preclinical vector production, and analytical assay development and validation from the site.

In June, Genezen told us the cell and gene therapy sector is evolving rapidly, and there is growing demand for capacity and expertise. “We are investing heavily to meet this need now and in the future.”

Academic partnerships 

The CDMO started out by teaming up with academic vector production facilities to utilize their excess production capacity, and will continue to provide cell manufacturing and patient sample testing through such alliances. “We are now expanding into a stand-alone facility while continuing our academic partnerships.”

The new facility, which will have a global focus in terms of target clients, is being funded by a majority investment from Ampersand Capital Partners, a private equity firm specializing in growth equity investments in the healthcare sector.

Cell expansion, banking

Once finished, the site will deliver aseptic manufacturing of lentiviral and retroviral vectors from multiple cGMP production suites and will offer capabilities for host cell expansion, host cell banking, and viral vector production via transient transfection and producer cell lines.

Analytical testing services, including recombinant competent lentivirus (RCL) testing, vector stability testing, and safety and sterility testing, will also be available.

In terms of capacity for viral vector production when the facility is fully operational, the company told us previously: “Capacity is difficult to define because of the variability between client vectors and the production platform the client chooses to use, but we will be continuing to grow with our client's needs.” 

Related news

Show more

Related products

show more

Liposomal and Nanoparticle Technology

Liposomal and Nanoparticle Technology

Pfizer CentreOne | 18-Nov-2022 | Technical / White Paper

Medical science is continuously searching for better ways to administer drugs into the body and to maximize the therapeutic effectiveness of the drugs...

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

GMP manufacturing of buffers and liquid blends

GMP manufacturing of buffers and liquid blends

Actylis – The Partner of Choice | 16-Nov-2022 | Technical / White Paper

Actylis manufactures buffers, process solutions, cleaning solutions, Water for Injection (WFI) for further processing, and custom liquid blends in compliance...

Related suppliers

Follow us

Products

View more

Webinars